|
Company:
|
IMMUNOGEN, INC. (IMGN)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
4/6/2023
|
|
CIK:
|
0000855654
|
|
Address:
|
830 WINTER ST
|
|
City, State, Zip:
|
WALTHAM, Massachusetts 02451
|
|
Telephone:
|
(781)895-0600
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$14.71
|
Change:
-0.44 (-2.90%)
|
Trade Time:
Jun 07
|
Market Cap:
$3.71B
|
|
|
|
|
|
|
Description of Business
|
|
We are a commercial-stage biotechnology company focused on developing and
commercializing the next generation of antibody-drug conjugates (ADCs) to
improve outcomes for cancer patients. By generating targeted therapies with
enhanced anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer patients more good days. We call
this our commitment to "target a better now."
An ADC with our proprietary technology comprises an antibody that binds to a
target found on tumor cells and is conjugated to one of our potent anti-cancer
agents as a "payload" to kill the tumor cell once the ADC has bound to its
target. ADCs are an expanding class of anticancer therapeutics, with twelve
approved products and the number of agents in development growing significantly
in recent years.
|
|
|
|